Kolexia
El Hajbi Farid Gastro-entérologie
El Hajbi Farid
Gastro-entérologie
Centre Oscar-Lambret
Lille, France
172 Activités
88 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Tumeurs de l'oesophage Carcinome épidermoïde de l'oesophage Adénocarcinome Tumeurs colorectales Tumeurs du pancréas Tumeurs de l'anus Carcinome neuroendocrine

Collaborateurs

Voir plus
Assi Fadi
Assi Fadi
Centre Hospitalier de Abbeville, Abbeville, France
Danielou Marie
Danielou Marie
Hôpital Antoine-Béclère, Clamart, France
Crumbach Jean-Pierre
Crumbach Jean-Pierre
Hopital De Saint Avold - Sos Sante, Saint-Avold, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France

Industries

Voir plus
A+A
496 collaboration(s)
Dernière en 2023
B3TSI
410 collaboration(s)
Dernière en 2023
P\S\L Group Services
288 collaboration(s)
Dernière en 2023
IQVIA
126 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
PROTECT: PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial
Essai Clinique (Centre Oscar-Lambret)   26 février 2024
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.
ESMO open   19 décembre 2023
CheckMate 648: A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
Essai Clinique (BMS)   30 novembre 2023
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
JAMA oncology   19 octobre 2023
1617P PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
ARION: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial
Essai Clinique (Unicancer)   30 août 2023
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   25 août 2023
BEVANEC: Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study
Essai Clinique (Hospices Civils de Lyon)   18 avril 2023
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
The Lancet. Oncology   02 février 2023